| Literature DB >> 29896274 |
Hao Gao1,2,3, Yong Gao1,2,3, Lingdi Yin1,2,3, Guangfu Wang1,2,3, Jishu Wei1,2,3, Kuirong Jiang1,2,3, Yi Miao1,2,3.
Abstract
Background: Pancreatic solid pseudopapillary tumors (SPTs) are rare neoplasms with low-grade malignancy. The main treatment for them is surgical resection. However, some SPTs relapse after resection. The risk factors associated with the recurrences of resected SPTs remain controversial to date. We performed a systematic review and meta-analysis to identify the risk factors of the recurrences of pancreatic SPTs. Materials andEntities:
Keywords: pancreatic solid pseudopapillary tumors; recurrence; risk factors
Year: 2018 PMID: 29896274 PMCID: PMC5995943 DOI: 10.7150/jca.24491
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
General characteristics of enrolled studies.
| Author | Year | Country | study design | Study period | Total cases | Casesfollowed up | Female (%) | Mean age (years) | Mean follow up time (months) | NOS |
|---|---|---|---|---|---|---|---|---|---|---|
| Xu et al. | 2017 | China | retrospective | 2008-2015 | 121 | 103 | 76.9 | 33.7 | 42.7 | 7 |
| Xu et al. | 2016 | China | retrospective | 2006-2014 | 148 | 116 | 79.1 | 30.8 | 32.6 | 7 |
| Marchegiani et al. | 2016 | Italy, USA | retrospective | 1986-2014 | 131 | 105 | 86.3 | 33* | 62* | 8 |
| Irtan et al. | 2016 | France | retrospective | 1996-2016 | 51 | 51 | 78 | 13.1* | 65* | 7 |
| Serrano et al. | 2014 | Canada | retrospective | 1999-2013 | 32 | 32 | 81.25 | 35.65 | 43* | 7 |
| Kang et al. | 2014 | South Korea | retrospective | 1990-2008 | 351 | 317 | 90.3 | 36.8 | Not mentioned | 8 |
| Hwang et al. | 2014 | South Korea | retrospective | 1992-2012 | 45 | 45 | 80 | 14.9 | 34* | 6 |
| Estrella et al. | 2014 | USA | retrospective | Not mentioned | 64 | 59 | 84 | 33 | 76* | 7 |
| Kim et al. | 2011 | South Korea | retrospective | 1995-2007 | 114 | 114 | 86.9 | 36* | 57* | 7 |
| Machado et al. | 2008 | Brazil | retrospective | 1990-2005 | 34 | 34 | 79 | 23* | 84 | 7 |
USA: the United States of America; *median; NOS: the Newcastle-Ottawa Quality Assessment Scale.
Pooled results and sensitivity analyses.
| Risk | Number of studies | Effects model | OR | 95%CI | P | I² | PH |
|---|---|---|---|---|---|---|---|
| Gender | 8 | Random | 0.75 | 0.30-1.88 | 0.54 | 0% | 0.96 |
| Fixed* | 0.70 | 0.29-1.71 | 0.43 | 0% | 0.96 | ||
| Tumor size | 3 | Random | 4.74 | 1.12-20.05 | 0.03 | 0% | 0.75 |
| Fixed* | 5.22 | 1.28-21.26 | 0.02 | 0% | 0.75 | ||
| Tumor size | 3 | Random | 6.11 | 2.29-16.27 | 0.0003 | 0% | 0.5 |
| Fixed* | 5.99 | 2.27-15.80 | 0.0003 | 0% | 0.5 | ||
| Location | 6 | Random | 0.58 | 0.26-1.28 | 0.17 | 0% | 0.79 |
| Fixed* | 0.53 | 0.24-1.14 | 0.10 | 0% | 0.79 | ||
| Lymphovascular invasion | 5 | Random | 10.54 | 3.50-31.77 | <0.0001 | 0% | 0.62 |
| Fixed* | 9.14 | 3.10-26.92 | <0.0001 | 0% | 0.62 | ||
| Perineural invasion | 5 | Random | 1.79 | 0.71-4.47 | 0.22 | 0% | 0.65 |
| Fixed* | 1.60 | 0.63-4.03 | 0.32 | 0% | 0.65 | ||
| Calcification | 3 | Random | 0.60 | 0.10-3.55 | 0.57 | 0% | 0.82 |
| Fixed* | 0.56 | 0.09-3.25 | 0.51 | 0% | 0.82 | ||
| Lymph node metastasis | 5 | Random | 6.58 | 1.92-22.57 | 0.003 | 0% | 0.76 |
| Fixed* | 5.89 | 1.76-19.72 | 0.004 | 0% | 0.76 | ||
| Synchronous metastasis | 3 | Random | 103.21 | 8.20-1298.97 | 0.0003 | 31% | 0.23 |
| Fixed* | 100.83 | 17.84-568.85 | <0.00001 | 31% | 0.23 | ||
| Positive margin | 6 | Random | 6.78 | 2.44-18.78 | 0.0002 | 0% | 0.96 |
| Fixed* | 6.82 | 2.51-18.55 | 0.0002 | 0% | 0.96 | ||
| Capsular invasion | 3 | Random | 8.86 | 0.77-101.46 | 0.08 | 60% | 0.08 |
| Fixed* | 5.15 | 1.38-19.18 | 0.01 | 60% | 0.08 |
*sensitivity analysis